Bio-Bridge Science Announces Allowance of All Claims of a Second U.S. Patent Application on the Papillomavirus Pseudovirus Techn
November 28 2006 - 12:49PM
Business Wire
Bio-Bridge Science, Inc.(OTCBB:BGES) a developer of vaccines with
broad preventative and therapeutic applications, is pleased to
announce that all the pending claims of a second patent application
on the papillomavirus pseudovirus technology have been allowed by
the U.S. Patent and Trademark Office. Bio-Bridge expects the second
patent will be issued upon payment of the issue fee. The first U.S.
patent (number 6,878,541 B2) on the papillomavirus pseudovirus
technology was issued in 2005. The second patent covers broader
aspects of the invention and further protects the intellectual
property in the papillomavirus pseudovirus technology. Loyola
University Chicago owns the patent and has exclusively licensed the
technology to Bio-Bridge Science, Inc. About Bio-Bridge Science:
Bio-Bridge Science (http://www.bio-bridge-science.com/) is a
biotechnology firm focused on the development of vaccines with
broad therapeutic and preventive applications. Bio-Bridge is
developing a promising new HIV Vaccine that is expected to enter
clinical trials in the near future in China. The vaccine, based on
exclusive technology co-developed by CEO Dr. Liang Qiao, an
associate professor at Loyola University Chicago's Strich School of
Medicine, targets infection in mucosal tissues, which is a unique
approach to prevent and treat HIV infection. Bio-Bridge Science's
GMP facility will also be used to develop vaccines against cervical
cancer and colon cancer under the same technology platform. The
company plans to develop these vaccines in the United States and
Japan in the future. Forward Looking Statements: This press release
contains forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying
assumptions and other statements that are other than statements of
historical facts. These statements are subject to uncertainties and
risks including, but not limited to, product and service demand and
acceptance, changes in technology, economic conditions, the impact
of competition and pricing, government regulation, and other risks
defined in this document and in statements filed from time to time
with the Securities and Exchange Commission. All such
forward-looking statements, whether written or oral, and whether
made by or on behalf of the company, are expressly qualified by
these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition,
the company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof. Please refer to SEC filings for additional information.
Bio-Bridge Science, Inc.(OTCBB:BGES) a developer of vaccines with
broad preventative and therapeutic applications, is pleased to
announce that all the pending claims of a second patent application
on the papillomavirus pseudovirus technology have been allowed by
the U.S. Patent and Trademark Office. Bio-Bridge expects the second
patent will be issued upon payment of the issue fee. The first U.S.
patent (number 6,878,541 B2) on the papillomavirus pseudovirus
technology was issued in 2005. The second patent covers broader
aspects of the invention and further protects the intellectual
property in the papillomavirus pseudovirus technology. Loyola
University Chicago owns the patent and has exclusively licensed the
technology to Bio-Bridge Science, Inc. About Bio-Bridge Science:
Bio-Bridge Science (http://www.bio-bridge-science.com/) is a
biotechnology firm focused on the development of vaccines with
broad therapeutic and preventive applications. Bio-Bridge is
developing a promising new HIV Vaccine that is expected to enter
clinical trials in the near future in China. The vaccine, based on
exclusive technology co-developed by CEO Dr. Liang Qiao, an
associate professor at Loyola University Chicago's Strich School of
Medicine, targets infection in mucosal tissues, which is a unique
approach to prevent and treat HIV infection. Bio-Bridge Science's
GMP facility will also be used to develop vaccines against cervical
cancer and colon cancer under the same technology platform. The
company plans to develop these vaccines in the United States and
Japan in the future. Forward Looking Statements: This press release
contains forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying
assumptions and other statements that are other than statements of
historical facts. These statements are subject to uncertainties and
risks including, but not limited to, product and service demand and
acceptance, changes in technology, economic conditions, the impact
of competition and pricing, government regulation, and other risks
defined in this document and in statements filed from time to time
with the Securities and Exchange Commission. All such
forward-looking statements, whether written or oral, and whether
made by or on behalf of the company, are expressly qualified by
these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition,
the company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof. Please refer to SEC filings for additional information.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024